Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Issues New Risk Classification Rule For GMP Inspections

This article was originally published in PharmAsia News

Executive Summary

The new risk-based regulation highlights recordkeeping and high-risk products with stricter enforcement for repeat offenders. Meanwhile, SFDA is also implementing an electronic monitoring system to improve drug safety.

You may also be interested in...



China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope

Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.

Hengrui Quickly Fills Celgene Void Amid Nationalism Surge In China

China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.

Topics

Related Companies

UsernamePublicRestriction

Register

SC081643

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel